Theravance Biopharma, Inc. announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). The initiative was introduced at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), held in Honolulu, Hawaii, October 5–9, 2025.
“The ‘Power in the Periphery’ campaign underscores our ongoing commitment to advancing education for healthcare professionals about the complex mechanisms underlying nOH,” said Rick E Winningham, Chief Executive Officer, Theravance Biopharma. “Through this initiative, we aim to deepen scientific understanding of nOH, particularly in the context of MSA, and foster meaningful engagement with clinicians on this challenging condition.”
Health Technology Insights: Brightwood Capital Provides Financing to Support Motor City Dental Partners’ Growth
nOH is a serious disorder that can significantly disrupt daily life, causing symptoms such as lightheadedness, fainting, fatigue, blurry vision, weakness, trouble concentrating, and head and neck pain. It is often seen in neurodegenerative disorders such as MSA. In MSA, neurodegeneration primarily affects the central nervous system, while many peripheral nerves that control blood pressure remain functional. With the launch of this educational initiative, Theravance aims to advance scientific understanding of MSA-related nOH and increase awareness of this debilitating condition.
About Multiple System Atrophy (MSA) and Symptomatic Neurogenic Orthostatic Hypotension (nOH)
MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system. The autonomic nervous system controls body functions that are mostly involuntary. One of the most frequent autonomic symptoms associated with MSA is a sudden drop in blood pressure upon standing (nOH).1 There are approximately 50,000 MSA patients in the US2 and 70-90% of MSA patients experience nOH symptoms.3 Despite available therapies, many MSA patients remain symptomatic with nOH.4
Neurogenic orthostatic hypotension (nOH) is a rare disorder defined as a fall in systolic blood pressure of ⩾20 mm Hg or diastolic blood pressure of ⩾10 mm Hg, within 3 minutes of standing. Severely affected patients are unable to stand for more than a few seconds because of their decrease in blood pressure, leading to cerebral hypoperfusion and syncope. A debilitating condition, nOH results in a range of symptoms including dizziness, lightheadedness, fainting, fatigue, blurry vision, weakness, trouble concentrating, and head and neck pain.
Health Technology Insights: LucyRx Acquires CerpassRx to Expand Prescription Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
